Biotechnology News and Research

RSS

Johnson & Johnson in talks to buy Crucell

Johnson & Johnson is in advanced negotiations to buy Dutch biotechnology company Crucell NV for €1.75 billion ($2.29 billion), the two companies said today. Giles Somers, senior healthcare analyst at Datamonitor comments:

19 Sep 2010

Generex Biotechnology convenes Special Meeting to approve amendment

Generex Biotechnology Corporation today announced that it convened a special meeting of stockholders (the "Special Meeting") on September 17, 2010 at 10:00 a.m. (local time) at the Meeting Rooms, Westin Harbour Castle Hotel, 1 Harbour Square, Toronto, Ontario Canada M5J 1A6.

18 Sep 2010

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

CytoGenix, Inc. today announced that it has initiated the process of testing CytoGenix's novel liner DNA technology on ferrets, with the expectations of a positive result, furthering the development of the vaccine candidate.

18 Sep 2010

Effective strategies to combat obesity epidemic among children and teenagers needed

September is National Childhood Obesity Awareness Month, drawing attention to the epidemic of obesity among children and adolescents in the United States. A multidisciplinary approach to assessment and intervention is crucial for effective weight management and should draw from the latest medical evidence, best practices, and innovative educational and policy initiatives, all of which are presented and debated in the new bimonthly, print and online journal Childhood Obesity, published by Mary Ann Liebert, Inc. The inaugural issue is available free online.

18 Sep 2010

Shrink enters final phase of commercialization program for StemDisc product line

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors, and biotechnology research and development tools businesses, announced today that it is entering the final phase of its commercialization program for its first cell culturing devices for the StemDisc family of stem cell culturing products.

18 Sep 2010

Researchers suggest potentially valuable role for minocycline plus N-acetylcysteine to treat TBI

Traumatic brain injury is a serious public health problem in the United States. Recent data show that approximately 1.7 million people sustain a traumatic brain injury annually. While the majority of TBIs are concussions or other mild forms, traumatic brain injuries contribute to a substantial number of deaths and cases of permanent disability.

18 Sep 2010

CMB initiates first human trial for plant-produced H1N1 influenza vaccine

Fraunhofer USA Center for Molecular Biotechnology (CMB) announced today it has initiated the first human trial of plant-produced H1N1 influenza vaccine at the Walter Reed Army Institute of Research Clinical Trials Center (WRAIR-CTC).

18 Sep 2010

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Ligand Pharmaceuticals Incorporated announced today that it has transferred exclusive license rights to Proximagen Limited for a series of compound hits related to the CXCR4 target with application for a number of indications including those related to the central nervous system. Ligand will receive an upfront payment and continue to be entitled to receive potential future milestone and royalty payments.

18 Sep 2010

Minocycline plus N-acetylcysteine may help treat TBI

Traumatic brain injury (TBI) is a serious public health problem in the United States. Recent data show that approximately 1.7 million people sustain a traumatic brain injury annually. While the majority of TBIs are concussions or other mild forms, traumatic brain injuries contribute to a substantial number of deaths and cases of permanent disability.

18 Sep 2010

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Elan Board unanimously accepts US law firm's report on legal breaches

Elan Corporation, plc announced that at yesterday's meeting of the Elan Board of Directors, the Board unanimously accepted a report prepared by the United States law firm of McKenna Long & Aldridge, LLP based upon a review it conducted. McKenna Long, serving as independent counsel to the Board, reviewed a number of matters brought to the Board's attention by certain Directors.

17 Sep 2010

Biotechnology Institute announces classroom program to improve U.S. life science education quality

Biotechnology industry leaders announced today a major new program to improve the quality of U.S. life science education. The Biotechnology Institute's new "Scientists in the Classroom" initiative is the life science industry's response to President Obama's "Educate to Innovate" campaign to improve the performance of America's students in science, technology, engineering, and mathematics (STEM) education.

17 Sep 2010

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, today announced the execution of an exclusive research collaboration and license agreement. The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia, Humira and Remicade utilized in the treatment of Crohn's Disease, and the subsequent development of diagnostic tests.

17 Sep 2010

Shrink Nanotechnologies files patent for CellAlign tissue engineering technology

Shrink Nanotechnologies, Inc., an innovative nanotechnology company developing products and licensing opportunities in the alternative energy industry, medical diagnostics and sensors and biotechnology research and development tools businesses, announced today that certain patent applications related to its advanced tissue engineering technology platform, CellAlign, have been filed.

17 Sep 2010

Researchers load biological molecules onto 'nanosprings'

Researchers at Oregon State University have reported the successful loading of biological molecules onto "nanosprings" - a type of nanostructure that has gained significant interest in recent years for its ability to maximize surface area in microreactors.

17 Sep 2010

Pharma Lynx licenses NewCardio's QTinno automated cardiac safety solution

NewCardio, Inc., a cardiovascular diagnostic solutions developer, announced today that Pharma Lynx, a global contract research organization and a subsidiary of Diverse Lynx, has signed an MSA to license NewCardio's QTinno™ solution for use in Phase 1 studies. Pharma Lynx has particular expertise in oncology studies, including QTc studies involving both healthy subjects and cancer patients, and QTinno will add to Pharma Lynx's already robust capabilities, enabling it to deliver fully automated QTc studies to its sponsors.

17 Sep 2010

Myrexis to present poster on cancer metabolism inhibitor program

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present a poster at the Cancer and Metabolism: Pathways to the Future meeting in Edinburgh, Scotland, as well as two additional posters at the 22nd European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium on "Molecular Targets and Cancer Therapeutics" November 16-19, 2010, in Berlin, Germany.

17 Sep 2010

Aerocrine directs issue of new shares, convertible bonds to Novo A/S

Aerocrine AB today announces that on 15 September 2010 the Board, by virtue of authorization by the shareholders' meeting, decided to carry out a SEK 225 million directed issue of new shares and convertible bonds to Denmark-based Novo A/S, as well as a SEK 155.5 million new share issue with preferential rights to existing shareholders.

17 Sep 2010

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Generex Biotechnology Corporation today announced presentations in respect of the technologies and development products of its wholly-owned subsidiary, Antigen Express, Inc. The presentations were made at the conference Gene based Vaccines: Optimizing Development and Delivery 2010 held September 13 and 14, 2010 in Vienna, Austria and at the Immunotherapeutics and Vaccine Summit held in Cambridge, MA from August 17-19, 2010.

17 Sep 2010

Pall launches GeneDisc Rapid Microbiology System for advanced microbial quality monitoring

Pall Corporation, a global leader in filtration, separation and purification, today announced the introduction of the GeneDisc® Rapid Microbiology System for advanced microbial quality monitoring. This system represents Pall's latest quality assurance innovation for the pharmaceutical manufacturing industry.

From Pall Corporation 17 Sep 2010

Biotechnology News and Research

Johnson & Johnson in talks to buy Crucell

Generex Biotechnology convenes Special Meeting to approve amendment

CytoGenix initiates novel liner DNA technology testing on ferrets for vaccine development

Effective strategies to combat obesity epidemic among children and teenagers needed

Shrink enters final phase of commercialization program for StemDisc product line

Researchers suggest potentially valuable role for minocycline plus N-acetylcysteine to treat TBI

CMB initiates first human trial for plant-produced H1N1 influenza vaccine

Ligand Pharmaceuticals transfers license rights to Proximagen for CXCR4 target

Minocycline plus N-acetylcysteine may help treat TBI

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Elan Board unanimously accepts US law firm's report on legal breaches

Biotechnology Institute announces classroom program to improve U.S. life science education quality

Prometheus, Tarrot announce exclusive agreement for Crohn's Disease treatment

Shrink Nanotechnologies files patent for CellAlign tissue engineering technology

Researchers load biological molecules onto 'nanosprings'

Pharma Lynx licenses NewCardio's QTinno automated cardiac safety solution

Myrexis to present poster on cancer metabolism inhibitor program

Aerocrine directs issue of new shares, convertible bonds to Novo A/S

Generex presents Ii-Key hybrids product development at Gene based Vaccines conference

Pall launches GeneDisc Rapid Microbiology System for advanced microbial quality monitoring

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News